Related references
Note: Only part of the references are listed.Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
J-P. Westwood et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center
Antoine Froissart et al.
CRITICAL CARE MEDICINE (2012)
Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis
Nay M. Tun et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura
Vinai C. Bhagirath et al.
TRANSFUSION (2012)
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
Marie Scully et al.
BLOOD (2011)
Survival and relapse in patients with thrombotic thrombocytopenic purpura
Johanna A. Kremer Hovinga et al.
BLOOD (2010)
How I treat patients with thrombotic thrombocytopenic purpura: 2010
James N. George
BLOOD (2010)
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature
Mischelle A. Elliott et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Rituximab as an Adjunct to Plasma Exchange in TTP: A Report of 12 Cases and Review of Literature
Sushama Jasti et al.
JOURNAL OF CLINICAL APHERESIS (2008)
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS 13-deficient thrombotic thrombocytopenic purpura:: a study of 11 cases
F Fakhouri et al.
BLOOD (2005)
Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab
PM Millward et al.
TRANSFUSION (2005)
Thrombotic thrombocytopenic purpura
B Lämmle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)
A Ahmad et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center
A Shamseddine et al.
JOURNAL OF CLINICAL APHERESIS (2004)
Rituximab in patients with refractory thrombotic thrombocytopenic purpura
S Sallah et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
J Boye et al.
ANNALS OF ONCOLOGY (2003)
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab
XL Zheng et al.
ANNALS OF INTERNAL MEDICINE (2003)
Rituximab - A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
GL Plosker et al.
DRUGS (2003)
Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab
J Chemnitz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Share Paper
